We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
- Authors
Sandborn, William J; Rutgeerts, Paul; Enns, Robert; Hanauer, Stephen B; Colombel, Jean-Frédéric; Panaccione, Remo; D'Haens, Geert; Li, Ju; Rosenfeld, Marie R; Kent, Jeffrey D; Pollack, Paul F
- Abstract
Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent.
- Publication
Annals of internal medicine, 2007, Vol 146, Issue 12, p829
- ISSN
1539-3704
- Publication type
Journal Article
- DOI
10.7326/0003-4819-146-12-200706190-00159